Lexicon Pharmaceuticals | LXRX - Loan Capital


Lexicon Pharmaceuticals reported $49.68M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Abbott USD 29.64B 19.74B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Illumina USD 1.49B 0 Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 37.53B 1.91B Mar/2026
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
MannKind USD 548.07M 371K Mar/2026
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Thermo Fisher Scientific USD 40.07B 4.22B Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024